株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオ医薬品の世界市場 - タイプ、用途、地域別 - 成長、トレンド、および予測

Biopharmaceuticals Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 390811
出版日 ページ情報 英文 114 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.31円で換算しております。
バイオ医薬品の世界市場 - タイプ、用途、地域別 - 成長、トレンド、および予測 Biopharmaceuticals Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年02月01日 ページ情報: 英文 114 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

世界のバイオ医薬品市場は、2018年から2023年にかけて、8.5%のCAGRで拡大し、2023年には3,411億6,000万米ドルに達すると予測されています。

当レポートでは、バイオ医薬品の世界市場を調査し、市場の概要、タイプ、治療用途、地域別の市場動向、市場規模の推移と予測、市場促進・阻害要因ならびに市場機会の分析、競合情勢、主要企業のプロファイルなど包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • サプライヤーの交渉力
    • 消費者の交渉力
    • 新規参入の脅威
    • 代替製品とサービスの脅威
    • 業界内での競争

第6章 成長要因、阻害要因、機会、課題の分析

  • 市場の成長要因
  • 市場の阻害要因
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 製品タイプ別
    • モノクローナル抗体
    • 組換成長因子
    • 精製タンパク質
    • 組換えタンパク質
    • 組換えホルモン
    • 合成免疫調節剤
    • ワクチン
  • 治療用途別
    • 腫瘍
    • 炎症性感染症
    • 自己免疫疾患
    • 代謝性疾患
    • ホルモン疾患
    • 疾患予防
    • 心血管疾患
    • 神経疾患
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 南米
    • 中東・アフリカ

第8章 競合情勢

  • M&A分析
  • 合意、提携、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Abbvie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lily & Co.
  • Johnson & Johnson
  • Novartis AG
  • Novo Nordisk Inc.
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Roche Holding AG
  • Others

第10章 市場の将来展望

目次
Product Code: 51323

Market Overview

The global biopharmaceuticals market was valued at USD 237,250.8 million in 2018, and is estimated to be valued at USD 388,997.3 million in 2024, witnessing a CAGR of 8.59%. The market growth is attributed to the growing acceptance for biopharmaceuticals due to their ability to treat previously untreatable diseases, resulting in huge market demand for biopharmaceuticals.

Biopharmaceuticals offer several benefits, such as highly effective and potent action, fewer side effects, and the potential to actually cure diseases rather than merely treat the symptoms, which have significantly increased the demand for biopharmaceutical products.

Biopharmaceuticals have reduced the number of deaths due to cancer and HIV/AIDS in the past decade, which has led to an increase in the adoption of biopharmaceuticals in the global market.

Biopharmaceuticals have given an alternative to the previously less effective and sometimes unsafe treatments, and it allows clinicians to tailor treatments to the specific medical problems experienced by each patient.

Scope of the Report

For the scope of the report, the term biopharmaceutical refers to any biologically synthesized molecule that is used to treat or manage disorders.

Key Market Trends

Monoclonal Antibodies are Expected to have the Largest Market Size

Among the given segments, monoclonal antibodies are believed to have the largest market size. This can be attributed to the growing research done with the help of monoclonal antibodies. On the other hand, the recombinant enzymes segment is expected to show rapid growth during the forecast period.

Monoclonal antibodies (mAbs) find their application in the areas of cancer treatment. Their use is becoming prevalent in developed countries, such as the United States and the United Kingdom. The mAb drugs in oncology are gaining momentum and growing at a decent pace. The segment is dominating the market currently, and the trend is expected to be followed in the future.

The recombinant enzymes, such as Enterokinase, are gaining attraction because of their efficacy in the digestion of the dietary proteins. Over the years, 100% native protein sequences have been produced using Enterokinase. This application has improved the market scope for this particular enzyme in the recent years.

North America is Expected to Dominate the Biopharmaceuticals Market

North America currently dominates the market for biopharmaceuticals, and is expected to continue its stronghold for a few more years. Asia-Pacific is expected to increase its market share in the future owing to increase in the prevalence of diseases, such as diabetes and cancer, along with the regulatory framework that is feasible for the approval of biopharmaceuticals in the region. The United States holds the majority of the market in the North American region; this is due to the increasing prevalence of chronic diseases. In addition, there is a rise in per capita health expenditure in the country that is expected to increase over the forecast period, owing to the decrease in the unemployment rate.

Competitive Landscape

The biopharmaceuticals market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products with less prices. Companies, like Amgen Inc., Eli Lily & Company, Johnson & Johnson, and Pfizer Inc. hold a significant share in the biopharmaceuticals market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Acceptance for Biopharmaceuticals
    • 4.2.2 Ability of Biopharmaceuticals to Treat Previously Untreatable Diseases
    • 4.2.3 Huge Market Demand
  • 4.3 Market Restraints
    • 4.3.1 Increasing Demand for Affordable Biopharmaceuticals
    • 4.3.2 High-end Manufacturing Requirements
    • 4.3.3 Complicated and Cumbersome Regulatory Requirements

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Monoclonal Antibodies
      • 5.1.1.1 Anti Cancer Monoclonal Antibodies
      • 5.1.1.2 Anti-inflammatory Monoclonal Antibodies
      • 5.1.1.3 Other Monoclonal Antibodies
    • 5.1.2 Recombinant Growth Factors
      • 5.1.2.1 Erythropoietin
      • 5.1.2.2 Granulocyte Colony Stimulating Factor
    • 5.1.3 Purified Proteins
      • 5.1.3.1 Leukemia Inhibitory Factor (LIF)
      • 5.1.3.2 P53 Protein
      • 5.1.3.3 P38 Protein
      • 5.1.3.4 Other Purified Proteins
    • 5.1.4 Recombinant Proteins
      • 5.1.4.1 Serum Albumin
      • 5.1.4.2 Amyloid Protein
      • 5.1.4.3 Defensin
      • 5.1.4.4 Transferrin
    • 5.1.5 Recombinant Hormones
      • 5.1.5.1 Recombinant Hormones
      • 5.1.5.2 Recombinant Insulin
      • 5.1.5.3 Other Recombinant Hormones
    • 5.1.6 Vaccines
      • 5.1.6.1 Recombinant Vaccines
      • 5.1.6.1.1 Cancer Vaccines
      • 5.1.6.1.2 Malaria Vaccines
      • 5.1.6.1.3 Ebola Vaccine
      • 5.1.6.1.4 Hepatitis-b Vaccine
      • 5.1.6.1.5 Tetanus Vaccine
      • 5.1.6.1.6 Diptheria Vaccine
      • 5.1.6.1.7 Cholera Vaccine
      • 5.1.6.1.8 Other Vaccines
      • 5.1.6.2 Conventional Vaccines
      • 5.1.6.2.1 Polio Vaccine
      • 5.1.6.2.2 Pox Vaccine
      • 5.1.6.2.3 Other Conventional Vaccines
      • 5.1.6.3 Recombinant Enzymes
      • 5.1.6.3.1 Enterokinase
      • 5.1.6.3.2 Cyclase
      • 5.1.6.3.3 Caspase
      • 5.1.6.3.4 Cathepsin
      • 5.1.6.4 Cell and Gene Therapies
      • 5.1.6.4.1 Allogeneic Products
      • 5.1.6.4.2 Autologous Products
      • 5.1.6.4.3 Acellular Products
      • 5.1.6.5 Other Product Types
      • 5.1.6.5.1 Blood Factors
      • 5.1.6.5.2 Other Product Types
    • 5.1.7 Synthetic Immunomodulators
      • 5.1.7.1 Cytokines, Interferones, Interleukins
      • 5.1.7.2 Tumor Necrosis Factor (TNF)
  • 5.2 By Therapeutic Application
    • 5.2.1 Oncology
    • 5.2.2 Inflammatory and Infectious Diseases
    • 5.2.3 Autoimmune Disorders
    • 5.2.4 Metabolic Disorders
    • 5.2.5 Hormonal Disorders
    • 5.2.6 Disease Prevention
    • 5.2.7 Cardiovascular Diseases
    • 5.2.8 Neurological Diseases
    • 5.2.9 Other Diseases
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 United Kingdom
      • 5.3.2.2 Germany
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 India
      • 5.3.3.2 China
      • 5.3.3.3 Japan
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 Eli Lily & Co.
    • 6.1.5 Johnson & Johnson
    • 6.1.6 Novartis AG
    • 6.1.7 Novo Nordisk Inc.
    • 6.1.8 Pfizer Inc.
    • 6.1.9 GlaxoSmithKline PLC
    • 6.1.10 Roche Holding AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS